Tuberculosis, Pulmonary Clinical Trial
Official title:
A Prospective, Randomized Pilot Study of the Immunomodulatory Effects of Azithromycin in Adults With Pulmonary Tuberculosis
Verified date | February 2024 |
Source | University Medical Center Groningen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Rationale: Treatment in tuberculosis (TB) is focused on eradication of the bacterial infection, however, after treatment approximately half of patients are left with a significant and permanent respiratory impairment. Adjunctive host-directed therapies are being investigated to modulate host immune responses to target mycobacterium tuberculosis (Mtb) infection and/or reduce excessive inflammation, prevent pathological tissue damage, preserve lung function and enhance effectiveness of standard drug therapy, while nonetheless eliminating Mtb. Macrolide antibiotics have previously been used in the treatment of multidrug-resistant TB. In addition to their antibiotic effects, macrolides have also been recognized to induce anti-inflammatory and immunomodulatory effects in other lung diseases. Objective: To investigate the immunomodulatory effects of azithromycin in tuberculosis patients receiving standard therapy (isoniazid, rifampicin, pyrazinamide, ethambutol (HRZE)) Study design: A prospective, randomized open label intervention trial to investigate the immunomodulatory effects of azithromycin Study population: 24 Intervention: azithromycin 250 mg once daily or standard of care (control) Main study parameters/endpoints: 1. To assess whether azithromycin enhances resolution of systemic inflammation in patients with drug susceptible pulmonary TB receiving standard treatment. 2. To assess whether azithromycin on top of standard treatment in patients with drug susceptible pulmonary TB reduces airway inflammation and reduces tissue degradation and remodeling 3. To investigate whether these effects are associated within shortening of the time to sputum conversion.
Status | Completed |
Enrollment | 24 |
Est. completion date | May 22, 2022 |
Est. primary completion date | May 22, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility | Inclusion Criteria: - Clinical diagnosis of drug sensitive pulmonary tuberculosis (molecular test; identification Mtb complex; absence of resistance genes such as rpob, inha, katg) - Written informed consent Exclusion Criteria: - Patient reported previous history of treatment for tuberculosis - Patients younger than 18 years - Pregnancy or breast feeding - Patients with hypersensitivity to macrolide antibiotics - Treatment with any macrolide in the previous month - Treatment with any tetracycline in the previous month - Treatment with any inhaled or oral corticosteroid in the previous month - Concomitant treatment with analgesic (NSAIDs)/immunosuppressant drugs (except paracetamol). - Treatment with digoxin - Patients with gastrointestinal complaints, like diarrhea and vomiting (=grade 2, observed) - Other known respiratory diseases, including bronchiectasis, pulmonary fibrosis, pulmonary vascular disease or lung cancer - HIV-1 infection or AIDS - Impaired liver function (Child-Pugh score C) - Patients with a known QTc =500 ms. An electrocardiogram (ECG) will be recorded. - Inability to spontaneously produce sputum upon diagnosis |
Country | Name | City | State |
---|---|---|---|
Netherlands | University Medical Center Groningen | Groningen |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Groningen |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Evaluation of HRZE treatment outcomes | Time to sputum conversion | Up to 6 months | |
Other | Evaluation of HRZE treatment outcomes | Drug exposure of HRZE in relation to minimal inhibitory concentration (MIC) of Mtb for HRZE | Up to 6 months | |
Other | Drug exposure of azithromycin | AUC0-24h of azithromycin in TB | Day 7 | |
Other | Drug exposure of azithromycin | Metabolic clearance (CLm) of azithromycin in TB | Day 7 | |
Other | Drug exposure of azithromycin | Volume of distribution (V) of azithromycin in TB | Day 7 | |
Other | Drug exposure of azithromycin | Elimination half-life (T1/2) of azithromycin in TB | Day 7 | |
Primary | Systemic inflammation | Changes in total & differential white blood cell counts markers | Before randomization, day 7 and day 28 | |
Primary | Systemic inflammation | Changes in serum inflammatory markers | Before randomization, day 7 and day 28 | |
Secondary | Pulmonary inflammation | Changes in total and differential sputum inflammatory cell counts | Before randomization and day 28 | |
Secondary | Pulmonary inflammation | Changes in cytokine levels in sputum | Before randomization and day 28 | |
Secondary | Pulmonary tissue degradation | Changes in markers of tissue degradation in sputum | Before randomization and day 28 | |
Secondary | Pulmonary tissue degradation | Changes in markers of tissue degradation in serum | Before randomization, day 7 and day 28 | |
Secondary | Pulmonary tissue remodeling | Changes in markers of tissue remodeling in sputum | Before randomization and day 28 | |
Secondary | Pulmonary tissue remodeling | Changes in markers of tissue remodeling in serum | Before randomization, day 7 and day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06084715 -
The INSTITUT Study
|
||
Terminated |
NCT03028129 -
Prevention of Tuberculosis in Prisons
|
Phase 4 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Withdrawn |
NCT03862248 -
Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
|
Phase 3 | |
Completed |
NCT03271567 -
Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Active, not recruiting |
NCT04919239 -
Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)
|
Phase 2 | |
Active, not recruiting |
NCT03251196 -
TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
|
||
Recruiting |
NCT05926466 -
BTZ-043 Dose Evaluation in Combination and Selection
|
Phase 2 | |
Recruiting |
NCT04752592 -
Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Not yet recruiting |
NCT04968886 -
TuBerculosis Viability Interregional Study and Agreement on Biological Tests
|
||
Not yet recruiting |
NCT04485156 -
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
|
Phase 3 | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT01364324 -
Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
|
||
Active, not recruiting |
NCT04179500 -
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers
|
Phase 2 | |
Completed |
NCT05899400 -
A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides
|
||
Completed |
NCT04938596 -
Airborne Preventive Measures to Reduce New TB Infections in Household Contacts
|
N/A | |
Recruiting |
NCT05455112 -
Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis
|
Phase 2 | |
Completed |
NCT03044158 -
GeneXpert Performance Evaluation for Linkage to Tuberculosis Care
|
N/A |